Table 2. Demographic and clinical characteristics of 6,669 patients with candidemia caused by Candida auris compared with other Candida species, South Africa, 2016–2017*.
| Characteristics | All candidemia | C. auris | Non–C. auris | C. parapsilosis | C. albicans | C. glabrata |
|---|---|---|---|---|---|---|
| No. case-patients |
6,669 |
794 |
5,875 |
2,600 |
1,353 |
598 |
| Systemic antifungal drug therapy <14 d before positive culture† |
317/1,829 (17.3) |
30/95 (31.6) |
287/1,734 (16.6) |
108/477 (22.6) |
36/441 (8.2) |
11/166 (6.6) |
| Azole |
219/317 (69.1) |
16/30 (53.3) |
203/287 (70.7) |
72/108 (66.7) |
30/36 (83.3) |
9/11 (81.8) |
| Polyene/amphotericin B |
38/317 (12) |
7/30 (23.3) |
31/287 (10.8) |
12/108 (11.1) |
5/36 (13.9) |
0/11 (0) |
| Echinocandin |
79/317 (24.9) |
13/30 (43.3) |
66/287 (23) |
27/108 (25) |
2/36 (5.6) |
2/11 (18.2) |
| Age, y, median (IQR) |
32 (0–58) |
54 (34–67) |
27 (0–57) |
24 (0–58) |
24 (0–56) |
54 (32–67) |
| Sex | ||||||
| Men and boys |
2,013/3,679 (54.7) |
284/463 (61.3) |
1,729/3,216 (53.8) |
806/1474 (54.7) |
533/978 (54.5) |
232/444 (52.3) |
| Women and girls |
1,666/3,679 (45.3) |
179/463 (38.7) |
1,487/3,216 (46.2) |
668/1,474 (45.3) |
445/978 (45.5) |
212/444 (47.7) |
| Length of hospital stay, d median (IQR) |
32 (16–54) |
55 (32–81) |
31 (15–52) |
40 (25–59) |
24 (12–43) |
22 (9–41) |
| Length of stay until first positive blood culture, d, median (IQR) |
13 (5–24) |
28 (15–46) |
12 (5–23) |
16 (10–27) |
10 (3–19) |
6 (1–16) |
| Province |
|
|
|
|
|
|
| Gauteng |
4,229/6,669 (63.4) |
680/794 (85.6) |
3,549/5,875 (60.4) |
1,651/2,600 (63.5) |
736/1,353 (54.4) |
323/598
(54) |
| Other |
2,440/ 6,669 (36.6) |
114/794 (14.4) |
2,326/5,875 (39.6) |
949/2,600 (36.5) |
617/1,353 (45.6) |
275/598
(46) |
| Healthcare sector |
|
|
|
|
|
|
| Public |
2,529/6,669 (37.9) |
99/794
(12.5) |
2,430/5,875 (41.4) |
599/2,600 (23) |
673/1,353 (49.7) |
248/598 (41.5) |
| Private |
4,140/6,669 (62.1) |
695/794 (87.5) |
3,445/5,875 (58.6) |
2,001/2,600 (77) |
680/1,353 (50.3) |
350/598 (58.5) |
| Hospital admission in past 12 mo |
1,428/1,967 (72.6) |
77/104
(74) |
1,351/1,863 (72.5) |
378/529
(71.5) |
341/486 (70.2) |
126/174 (72.4) |
| Intensive care unit admission |
1,579/2,167 (72.9) |
110/125
(88) |
1,469/2,042 (71.9) |
502/606
(82.8) |
377/539 (69.9) |
133/190
(70) |
| Mechanical ventilation |
611/1,818
(33.6) |
44/91
(48.4) |
567/1,727
(32.8) |
175/476
(36.8) |
129/440 (29.3) |
57/165 (34.6) |
| Central venous catheter in situ |
1,031/1,817 (56.7) |
69/92
(75) |
962/1,725
(55.8) |
289/479
(60.3) |
229/443 (51.7) |
89/165 (53.9) |
| Systemic antimicrobial drug therapy in 14 d before positive culture |
1,292/1,830 (70.6) |
77/94
(81.9) |
1,215/1,736
(70) |
349/481
(72.6) |
284/441 (64.4) |
105/164 (64.0) |
| Crude in-hospital case-fatality ratio | 8,39/1,966 (42.7) | 46/102 (45.1) | 793/1,864 (42.5) | 166/516 (32.2) | 247/492 (50.2) | 91/179 (50.8) |
*Values are no. (%) except as indicated. The 3 most common Candida species in the non–C. auris group (C. parapsilosis, C. albicans, and C. glabrata) are shown separately for comparison. For the purpose of this analysis, cases of candidemia with no final species identification were included in the non–C. auris group. IQR, interquartile range. †Patients could have received >1 class of antifungal drug therapy.